the recent approval of imetelstat in lr-mds based on results of the imerge trial
Published 1 month ago • 469 plays • Length 1:25Download video MP4
Download video MP3
Similar videos
-
2:51
analysis of the imerge trial: the disease-modifying potential of imetelstat in lr-mds
-
4:32
recent advances in the treatment of lr-mds: commands and imerge trial data
-
2:40
imerge results: efficacy and disease-modifying activity of imetelstat in lr-mds after esa failure
-
2:44
latest updates in the treatment of lr-mds: commands and imerge trials
-
2:57
imetelstat for lr-mds: insights from the imerge trial
-
1:44
imerge update: continuous transfusion independence & disease modification with imetelstat in lr-mds
-
1:51
treatment schedule for ruxolitinib in patients with mpns and how to assess response
-
1:25
imerge subgroup study: imetelstat in patients with lr-mds previously exposed to esas
-
38:36
spectra open biomedical imaging // ft. jean rintoul
-
11:24
progress report i - emese fürst
-
21:49
ravi vij in discussion with dr. jesus gonzalez lugo, md, on mds: how he intend to use imetelstat
-
3:08
htert reduction by imetelstat correlates with clinical activity in mds
-
2:33
insights into the results and implications of the commands & imerge studies in lr-mds
-
1:44
an update on imetelstat in r/r myelofibrosis
-
1:30
the safety profile of imetelstat in myeloid malignancies
-
1:46
how would the approval of luspatercept benefit the treatment landscape in myelofibrosis
-
4:39
imetelstat shows promise in advanced myelofibrosis
-
1:45
a phase ii study of elritercept for lower-risk mds
-
2:31
emerging treatment options for patients with esa-refractory mds: luspatercept & imetelstat
-
1:49
evaluating erythroid precursors in patients with lr-mds to predict response to esas
-
3:37
biomarker analysis of luspatercept versus epoetin alfa in lr-mds in the phase iii commands study
-
1:50
novel treatment regimens under investigation for richter's transformation